[Natalie8]

I didn't see any announcements of this on the forum in earlier listings.

This was published a few days ago. The article says that for those on Tysabri for 12 and 18 months the risk of PML is still WELL below one in 1,000. One analyst from Deutsche Bank claims the rate is actually approaching one in 1,000 for those on Tysabri for more than 24 months. 43,000 people are now on the drug.

http://online.wsj.com/article/BT-CO-...24-714686.html

Another article reads "The PML incidence remains below the long-projected risk of one in 1,000 patients developing the infection. After the previous case, a Jefferies & Co. research note last month put the revised PML incidence at one in 2,490 after 12- month Tysabri therapy; one in 1,400 after 18-month therapy; and one in 680 after 24-month therapy."

http://www.nasdaq.com/aspx/company-n...tysabri-update